Correction to Lancet Gastroenterol Hepatol 2017; 2: 877-89

No authors listed

Published Erratum

No authors listed. Lancet Gastroenterol Hepatol. 2018 Jan.

. 2018 Jan;3(1):e1.

doi: 10.1016/S2468-1253(17)30370-9.

No abstract available

Erratum for

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. Bazinet M, et al. Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889. doi: 10.1016/S2468-1253(17)30288-1. Epub 2017 Sep 28. Lancet Gastroenterol Hepatol. 2017. PMID: 28964701 Clinical Trial.